# OnCo record conko-003 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/conko-003/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "conko-003", "NCT00786058" ;
  schema:name "CONKO-003 (OFF)"@en ;
  schema:alternateName "CONKO 003"@en, "OFF regimen trial"@en, "Oxaliplatin, folinic acid and fluorouracil second line"@en ;
  schema:description "CONKO-003 was the first randomised trial to show a second-line chemotherapy helps in pancreatic cancer: adding oxaliplatin to fluorouracil after gemcitabine failed lengthened median survival from 3.3 to 5.9 months, which is why oxaliplatin-based second-line treatment is in the NICE guideline. A later Canadian trial with a different oxaliplatin schedule found the opposite."@en ;
  schema:url <https://onco.cc/trials/conko-003/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00786058>, <https://doi.org/10.1200/JCO.2013.53.6995>, <https://doi.org/10.1200/JCO.2016.68.5776> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/locally-advanced-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/leucovorin/>, <https://onco.cc/drugs/folfox/> ;
  onco:institutions <https://onco.cc/institutions/charite/> ;
  onco:terms <https://onco.cc/terms/peripheral-neuropathy/> .